Committee to Ponder Tumor Cells for Vaccine Manufacture
By Catherine Shaffer
Wednesday, September 19, 2012
The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) released briefing documents in advance of its Wednesday meeting to discuss the use of cell lines derived from human tumors for vaccine manufacture.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.